

03. - 17. April
2025



HUMANARZNEIMITTEL - EMA	2
<i>Allgemeines – General</i>	2
<i>Pharmakovigilanz – PRAC</i>	2
<i>Zulassung – Regulatory Affairs</i>	3
<i>Orphan Drugs und neuartige Therapierichtungen (ATMP)</i>	4
<i>Qualität – Quality</i>	4
<i>(Prä-) Klinische Forschung – Research and Development</i>	4
<i>Kinderarzneimittel – Paediatrics</i>	5
<i>Pflanzliche Arzneimittel – Herbal medicines</i>	5
EUROPEAN COMMISSION	6
EDQM	7
MEDIZINPRODUKTE	8
CMDH	9
HUMANARZNEIMITTEL - DEUTSCHLAND	10
HUMANARZNEIMITTEL - ÖSTERREICH	11
HUMANARZNEIMITTEL - SCHWEIZ	12
	
FRAGEN AN DAS NETZWERK	13
VERANSTALTUNGEN / EVENTS – BEHÖRDEN UND ANDERE VERANSTALTER	14
DEUTSCHLAND	14
ÖSTERREICH	14
SCHWEIZ	14
EUROPA	14
<u>Urheberrechtshinweis:</u>	

Der MEGRA Newsletter und die darin enthaltenen Beiträge sind urheberrechtlich geschützt. Ohne die ausdrückliche Genehmigung der Urheber oder der Inhaber der Nutzungsrechte darf weder der MEGRA Newsletter noch Teile davon verbreitet, bearbeitet, öffentlich zugänglich, vorgetragen, in einem Abrufsystem gespeichert oder in ein solches eingeführt oder in einer beliebigen anderen Form (elektronisch, mechanisch, per Hyperlink, per Fotokopie, per Aufzeichnung oder auf anderem Wege) oder zu einem beliebigen anderen Zweck vervielfältigt oder übermittelt werden. Downloads und Kopien des Newsletters sind nur Mitgliedern der *Mittel Europäischen Gesellschaft für Regulatory Affairs e.V. (MEGRA)* und für den privaten, nicht kommerziellen Gebrauch gestattet. Durch das Herunterladen oder Kopieren von Inhalten werden keine Rechte bezüglich der Inhalte übertragen.

Humanarzneimittel - EMA

Allgemeines – General

Real-world evidence

Published on: 08 - April - 2025

For more information, please refer to:

<https://www.ema.europa.eu/en/about-us/how-we-work/data-regulation-big-data-other-sources/real-world-evidence>

List of industry subject matter experts and list of planned calls for industry subject matter experts

Published on: 10 - April - 2025

For more information, please refer to:

https://www.ema.europa.eu/en/documents/other/list-industry-subject-matter-experts-list-planned-calls-industry-subject-matter-experts_en.pdf

News: Tackling vulnerabilities in the supply chain of radiopharmaceuticals in the EU

Published on: 10 - April - 2025

For more information, please refer to:

<https://www.ema.europa.eu/en/news/tackling-vulnerabilities-supply-chain-radiopharmaceuticals-eu>

Fees payable to the European Medicines Agency

Published on: 15 - April - 2025

For more information, please refer to:

<https://www.ema.europa.eu/en/about-us/fees-payable-european-medicines-agency>

Medicinal products for human use: monthly figures - March 2025

Published on: 16 - April - 2025

For more information, please refer to:

https://www.ema.europa.eu/en/documents/report/medicinal-products-human-use-monthly-figures-march-2025_en.pdf

Pharmakovigilanz – PRAC

List of signals discussed at PRAC since September 2012

Published on: 07 - April - 2025

For more information, please refer to:

https://www.ema.europa.eu/en/documents/other/list-signals-discussed-prac-september-2012_en.xlsx

Chapter 3.II: XEVPRM detailed user guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA

Published on: 10 - April - 2025

For more information, please refer to:

https://www.ema.europa.eu/en/documents/other/chapter-3ii-xevprm-detailed-user-guidance-electronic-submission-information-medicinal-products-human-use-marketing-authorisation-holders-ema_en.pdf

Humanarzneimittel - EMA

Guidance on the anonymisation of protected personal data and assessment of commercially confidential information during the preparation of RMPs (main body and annexes 4 and 6)

Published on: 11 - April - 2025

For more information, please refer to:

https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-anonymisation-protected-personal-data-assessment-commercially-confidential-information-during-preparation-rmps-main-body-annexes-4-6_en.pdf

Zulassung – Regulatory Affairs

Substance Management System (SMS) guidance for external users

Published on: 04 - April - 2025

For more information, please refer to:

https://www.ema.europa.eu/en/documents/other/sms-guidance-external-users_en.pdf

Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 24-27 March 2025

Published on: 09 - April - 2025

For more information, please refer to:

https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-24-27-march-2025_en.pdf

PRIME: priority medicines

Published on: 09 - April - 2025

For more information, please refer to:

<https://www.ema.europa.eu/en/human-regulatory-overview/research-development/prime-priority-medicines>

QRD Appendix V - Adverse-drug-reaction reporting details

Published on: 09 - April - 2025

For more information, please refer to:

https://www.ema.europa.eu/en/documents/template-form/qrd-appendix-v-adverse-drug-reaction-reporting-details_en.docx

Electronic submission of Article 57(2) data: questions and answers

Published on: 10 - April - 2025

For more information, please refer to:

https://www.ema.europa.eu/en/documents/other/electronic-submission-article-572-data-questions-answers_en.pdf

Questions & answers - Practical arrangements on the companion diagnostics consultation procedure to the European Medicines Agency by notified bodies - tracked changes

Published on: 11 - April - 2025

For more information, please refer to:

https://www.ema.europa.eu/en/documents/other/questions-answers-practical-arrangements-companion-diagnostics-consultation-procedure-european-medicines-agency-notified-bodies-tracked-changes_en.pdf

Humanarzneimittel - EMA

Product-information (QRD) templates – Human

Published on: 14 - April - 2025

For more information, please refer to:

<https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/product-information-requirements/product-information-qrd-templates-human>

Nitrosamines Safety Operational Expert Group

Published on: 15 - April - 2025

For more information, please refer to:

<https://www.ema.europa.eu/en/committees/working-parties-other-groups/chmp/nitrosamines-safety-operational-expert-group>

Orphan Drugs und neuartige Therapierichtungen (ATMP)

No news published

Qualität – Quality

Guidance on good manufacturing practice and good distribution practice: Questions and answers

Published on: 08 - April - 2025

For more information, please refer to:

<https://www.ema.europa.eu/en/human-regulatory-overview/research-development/compliance-research-development/good-manufacturing-practice/guidance-good-manufacturing-practice-good-distribution-practice-questions-answers>

(Prä-) Klinische Forschung – Research and Development

ICH Guideline M13B on bioequivalence for immediate-release solid oral dosage forms - additional strengths biowaiver - Scientific guideline, New

Published on: 09 - April - 2025

For more information, please refer to:

<https://www.ema.europa.eu/en/ich-guideline-m13b-bioequivalence-immediate-release-solid-oral-dosage-forms-additional-strengths-biowaiver-scientific-guideline>

Non-clinical Working Party

Published on: 15 - April - 2025

For more information, please refer to:

<https://www.ema.europa.eu/en/committees/working-parties-other-groups/chmp/non-clinical-working-party>

ICH M15 guideline on general principles for model-informed drug development - Step 2b - Scientific guideline

Published on: 16 - April - 2025

For more information, please refer to:

<https://www.ema.europa.eu/en/ich-m15-guideline-general-principles-model-informed-drug-development-step-2b-scientific-guideline>

Kinderarzneimittel – Paediatrics

Procedural advice on paediatric applications

Published on: 15 - April - 2025

For more information, please refer to:

https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-advice-paediatric-applications_en.pdf

Pflanzliche Arzneimittel – Herbal medicines

HMPC meeting report on European Union herbal monographs, guidelines and other activities - 17-19 March 2025

Published on: 10 - April - 2025

For more information, please refer to:

https://www.ema.europa.eu/en/documents/committee-report/hmhc-meeting-report-european-union-herbal-monographs-guidelines-other-activities-17-19-march-2025_en.pdf

Procedures for monograph and list entry establishment

Published on: 15 - April - 2025

For more information, please refer to:

<https://www.ema.europa.eu/en/human-regulatory-overview/herbal-medicinal-products/procedures-monograph-list-entry-establishment>

Herbal: Crataegi folium cum flore, F: Assessment finalized

Published on: 15 - April - 2025

For more information, please refer to:

<https://www.ema.europa.eu/en/medicines/herbal/crataegi-folium-cum-flore>

Herbal: Arnicae flos, F: Assessment finalized

Published on: 15 - April - 2025

For more information, please refer to:

<https://www.ema.europa.eu/en/medicines/herbal/arnicae-flos>

Herbal: Allii sativi bulbus, F: Assessment finalized

Published on: 15 - April - 2025

For more information, please refer to:

<https://www.ema.europa.eu/en/medicines/herbal/allii-sativi-bulbus>

European Commission

EU-EEA EFTA negotiations on health emergency measures in medical countermeasures to strengthen European health security

Published on: 14 – April – 2025

For more information, please refer to:

https://health.ec.europa.eu/latest-updates/eu-eea-efta-negotiations-health-emergency-measures-medical-countermeasures-strengthen-european-2025-04-14_en

Commission authorises medicine for treatment of early Alzheimer's disease

Published on: 15 – April – 2025

For more information, please refer to:

<https://ec.europa.eu/newsroom/sante/newsletter-archives/62476>

Commission welcomes significant step towards Pandemic Agreement

Published on: 16 - April - 2025

For more information, please refer to:

https://ec.europa.eu/commission/presscorner/detail/en/ip_25_1068

Health Technology Assessment: First joint clinical assessments begin

Published on: 16 – April – 2025

For more information, please refer to:

<https://ec.europa.eu/newsroom/sante/newsletter-archives/62551>

Outcome of the 181st session of the European Pharmacopoeia Commission, March 2025***Published on:*** 08 - April - 2025***For more information, please refer to:***

<https://www.edqm.eu/en/-/outcome-of-the-181st-session-of-the-european-pharmacopoeia-commission-march-2025>

EPC adopts groundbreaking chapter on cell-based preparations for human use***Published on:*** 08 - April - 2025***For more information, please refer to:***

<https://www.edqm.eu/en/-/epc-adopts-groundbreaking-chapter-on-cell-based-preparations-for-human-use>

Public consultation on revised general chapter 5.1.6. Alternative methods for control of microbiological quality in Pharmeuropa 37.2***Published on:*** 08 - April - 2025***For more information, please refer to:***

<https://www.edqm.eu/en/-/public-consultation-on-revised-general-chapter-5.1.6.-alternative-methods-for-control-of-microbiological-quality-in-pharmeuropa-37.2>

Certification monthly report of activities: End of March 2025***Published on:*** 10 - April - 2025***For more information, please refer to:***

<https://www.edqm.eu/en/-/certification-monthly-report-of-activities-end-of-march-2025>

Technical recommendation of the EDSForm WP: sulfamethoxazole-trimethoprim, paediatric products***Published on:*** 15 - April - 2025***For more information, please refer to:***

<https://www.edqm.eu/en/-/technical-recommendation-of-the-edsform-wp-sulfamethoxazole-trimethoprim-paediatric-products>

Medizinprodukte

New publication of Harmonised standards under the medical devices Regulations – April 2025

Published on: 10 - April - 2025

For more information, please refer to:

https://health.ec.europa.eu/medical-devices-topics-interest/harmonised-standards_en

Medical devices

Published on: 11 - April - 2025

For more information, please refer to:

<https://www.ema.europa.eu/en/human-regulatory-overview/medical-devices>

AR template for paediatric studies submitted in accordance with Article 46 of Regulation (EC) No1901/2006

Published on: 09 - April - 2025

For more information, please refer to:

<https://www.hma.eu/human-medicines/cmdh/templates/assessment-reports/paediatric-data.html>

CMDH PRESS RELEASES 2025

Published on: 09 - April - 2025

For more information, please refer to:

<https://www.hma.eu/human-medicines/cmdh/press-releases.html#c7615>

HMPWG Reports

Published on: 08 - April - 2025

For more information, please refer to:

<https://www.hma.eu/about-hma/working-groups/homeopathic-medicinal-products-working-group/homeopathic-medicinal-products-working-group-hmpwg.html#c6613>

Simultaneous National Scientific Advice (SNSA)

Published on: 10 - April - 2025

For more information, please refer to:

<https://www.hma.eu/about-hma/working-groups/eu-innovation-network-eu-in/eu-innovation-network-eu-in.html#c6787>

UPDATE - AR template for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006

Published on: 09 – April – 2025

For more information, please refer to:

https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fwww.hma.eu%2Ffileadmin%2Fdateien%2FHuman_Medicines%2FCMD_h_%2FTemplates%2FAR%2Fpaediatric_Data%2FCMDh_021_2009_Rev.6_2022_06_-_PAR_for_paediatric_studies_Art_45.doc&wdOrigin=BROWSELINK

UPDATE - Report from the meeting held on 25-26 March 2025

Published on: 09 – April – 2025

For more information, please refer to:

https://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/CMDh_pressreleases/2025/CMDh_press_release_-_March_2025.pdf

Concerned Member State's Comments on Lead Member State's Preliminary assessment report

Published on: 09 – April – 2025

For more information, please refer to:

https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fwww.hma.eu%2Ffileadmin%2Fdateien%2FHuman_Medicines%2FCMD_h_%2FTemplates%2FPSUR%2FCMDh_333_2015_Rev2_2025_04_clean_-_CMS_Comments_on_LMS_AR.docx&wdOrigin=BROWSELINK

Humanarzneimittel - Deutschland

Maßnahmen des BfArM und ergänzende Informationen zu Lieferengpässen

Veröffentlicht am: 07 - April - 2025

Weitere Informationen finden Sie unter:

https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Lieferengpaesse/Massnahmen-des-BfArM/_artikel.html?nn=986770

Informationen zu Einreichung und Genehmigung von Schulungsmaterial

Veröffentlicht am: 08 - April - 2025

Weitere Informationen finden Sie unter:

https://www.bfarm.de/DE/Arzneimittel/Pharmakovigilanz/Risikoinformationen/Schulungsmaterial/Zusatzinformationen/_artikel.html?nn=986770

Nachträgliche Änderungen einer klinischen Prüfung

Veröffentlicht am: 08 - April - 2025

Weitere Informationen finden Sie unter:

https://www.bfarm.de/DE/Arzneimittel/Klinische-Pruefung/Genehmigungsverfahren/Nachtraegliche-Aenderungen/_artikel.html?nn=986770

PSUR Single Assessment (PSUSA)

Veröffentlicht am: 15 - April - 2025

Weitere Informationen finden Sie unter:

https://www.bfarm.de/DE/Arzneimittel/Pharmakovigilanz/Periodic-Safety-Update-Reports_PSURs/PSUR-Single-Assessment/_artikel.html?nn=986770

Medizinforschungsgesetz

Veröffentlicht am: 16 - April - 2025

Weitere Informationen finden Sie unter:

https://www.bfarm.de/DE/Medizinforschungsgesetz/_artikel.html?nn=986770

Aktuell laufende und bestätigte Arzneimittel-Härtefallprogramme

Veröffentlicht am: 16 - April - 2025

Weitere Informationen finden Sie unter:

<https://www.bfarm.de/DE/Arzneimittel/Klinische-Pruefung/Compassionate-Use/compUse-tabelle.html?nn=986770>

Arzneimittel-Lieferengpass-bekämpfungs- und Versorgungs-verbesserungs-gesetz (ALBVVG)

Veröffentlicht am: 16 - April - 2025

Weitere Informationen finden Sie unter:

https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/Lieferengpaesse/ALBVVG/_artikel.html?nn=986770

Humanarzneimittel - Österreich

CHMP Meeting Highlights März 2025

Veröffentlicht am: 07 - April - 2025

Weitere Informationen finden Sie unter:

<https://www.basq.gv.at/marktbeobachtung/amtliche-nachrichten/detail/chmp-meeting-highlights-maerz-2025>

0425_Bearbeitungsstand

Veröffentlicht am: 10 - April - 2025

Weitere Informationen finden Sie unter:

[Gute Herstellungs- / Vertriebspraxis \(GMP/GDP\)](#)

0425_Register Arzneimittelvermittler

Veröffentlicht am: 10 - April - 2025

Weitere Informationen finden Sie unter:

[Arzneimittelvermittler](#)

0425_Register bewilligter AM Betriebe Österreich

Veröffentlicht am: 10 - April - 2025

Weitere Informationen finden Sie unter:

[Arzneimittelbetriebe](#)

Klinische Prüfungen von Arzneimitteln Neu

Veröffentlicht am: 11 - April - 2025

Weitere Informationen finden Sie unter:

<https://www.basq.gv.at/gesundheitsberufe/klinische-studien/klinische-pruefungen-von-arzneimitteln>

Beratung durch das BASG

Veröffentlicht am: 15 - April - 2025

Weitere Informationen finden Sie unter:

<https://www.basq.gv.at/fuer-unternehmen/arzneimittel-informationen/beratung-durch-das-basg>

PSUR outcome: Tiagabin

Veröffentlicht am: 07 - April - 2025

Weitere Informationen finden Sie unter:

[Link zur Website der EMA](#)

PSUR outcome: Capecitabin

Veröffentlicht am: 15 - April - 2025

Weitere Informationen finden Sie unter:

[Mustertext Capecitabin](#)

[Link zur Website der Europäischen Kommission](#)

PSUR outcome: Busulfan

Veröffentlicht am: 15 - April - 2025

Weitere Informationen finden Sie unter:

[Link zur Website der EMA](#)

Humanarzneimittel - Schweiz

Aktualisierte Vorgabedokumente

Veröffentlicht am: 14 - April - 2025

Weitere Informationen finden Sie unter:

https://www.swissmedic.ch/swissmedic/de/home/news/updates/updated_documents/april-2025.html



Fragen an das Netzwerk

Falls Sie eine Frage haben, die Sie gerne in unserem Netzwerk diskutieren würden, senden Sie uns einfach eine E-Mail an info-as@megra.org zur anonymen Publikation im nächsten Newsletter.*

*Bei der Beantwortung der Fragen handelt es sich um eine Zusammenfassung von persönlichen Meinungen und Erfahrungswerten der MEGRA Mitglieder mit keinem Anspruch auf Rechtssicherheit. Wir empfehlen zur Absicherung die Konsultation entsprechender zugrunde liegender Regularien.

Veranstaltungen / Events – Behörden und andere Veranstalter

Deutschland

BfArM im Dialog „D-A-CH-Anwenderforum SNOMED CT“

Ort: BfArM Webex Event

Termin: 20 – Mai - 2025

Weitere Informationen finden Sie unter:

<https://www.bfarm.de/DE/Aktuelles/Veranstaltungen/Termine/2025-05-20-snomed-anwenderforum.html?nn=986770>

Österreich

BASG-Gespräch: Digitalisierung im regulatorischen Umfeld – Status und Neuigkeiten

Ort: online via Zoom

Termin: 11 – Juni - 2025

Weitere Informationen finden Sie unter:

<https://www.ages.at/ages/veranstaltungen/veranstaltungskalender/detail/basg-gespraech-digitalisierung-im-regulatorischen-umfeld-status-und-neuigkeiten-1>

Schweiz

Keine Veranstaltungen veröffentlicht

Europa

SPOR and XEVMPD status update webinar

Where: Live broadcast

Date: 09 - April - 2025

For more information, please refer to:

<https://www.ema.europa.eu/en/events/spor-xevmpd-status-update-webinar>

Questions and answers clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - April 2025, May 2025 and June 2025

Where: online and European Medicines Agency, Amsterdam, the Netherlands

Date: 26 - April - 2025, 19 - May - 2025 and 17 - June - 2025

For more information, please refer to:

<https://www.ema.europa.eu/en/events/questions-answers-clinic-product-management-service-pms-product-user-interface-pui-application-programming-interface-api-april-2025>

<https://www.ema.europa.eu/en/events/questions-answers-clinic-product-management-service-pms-product-user-interface-pui-application-programming-interface-api-may-2025>

<https://www.ema.europa.eu/en/events/questions-answers-clinic-product-management-service-pms-product-user-interface-pui-application-programming-interface-api-june-2025>

Veranstaltungen / Events – Behörden und andere Veranstalter

EMA traineeship programme informative session

Where: online and European Medicines Agency, Amsterdam, the Netherlands

Date: 14 - April - 2025

For more information, please refer to:

<https://www.ema.europa.eu/en/events/ema-traineeship-programme-informative-session-0>

Second EMA / Alliance for Regenerative Medicine bilateral meeting

Where: online and European Medicines Agency, Amsterdam, the Netherlands

Date: 08 - May - 2025

For more information, please refer to:

<https://www.ema.europa.eu/en/events/second-ema-alliance-regenerative-medicine-bilateral-meeting>

EMA Open Door Day

Where: European Medicines Agency, Amsterdam, the Netherlands

Date: 09 - May - 2025

For more information, please refer to:

<https://www.ema.europa.eu/en/events/ema-open-door-day>

Clinical Trials Information System (CTIS): Walk-in clinic - May 2025

Where: online and European Medicines Agency, Amsterdam, the Netherlands

Date: 14 - May - 2025

For more information, please refer to:

<https://www.ema.europa.eu/en/events/clinical-trials-information-system-ctis-walk-clinic-may-2025>

Product Management Service (PMS) information day 2025

Where: online and European Medicines Agency, Amsterdam, the Netherlands

Date: 21 - May - 2025

For more information, please refer to:

<https://www.ema.europa.eu/en/events/product-management-service-pms-information-day-2025>

EUDAMED - 21 May Stuttgart Workshop registration is open

Where: online and Steigenberger Graf Zeppelin hotel, 70173 Stuttgart

Date: 21 - May - 2025

For more information, please refer to:

<https://www.eap-events.eu/ehome/index.php?eventid=200286344&>

Clinical Trials Information System (CTIS): Information day

Where: online and European Medicines Agency, Amsterdam, the Netherlands

Date: 22 - May - 2025

For more information, please refer to:

<https://www.ema.europa.eu/en/events/clinical-trials-information-system-ctis-information-day-1>

Veranstaltungen / Events – Behörden und andere Veranstalter

CPhI China 2025

Where: Shanghai, China

Date: 24 to 26 - June - 2025

For more information, please refer to:

<https://www.edqm.eu/en/cphi-china-2025>

EMA's 30th anniversary scientific conference - Medicines, regulation and the future

Where: European Medicines Agency, Amsterdam, the Netherlands

Date: 25 - June - 2025

For more information, please refer to:

<https://www.ema.europa.eu/en/events/emas-30th-anniversary-scientific-conference-medicines-regulation-future>